GNFTF News and Press, Genfit Ord From 02/14/19

Editor's note: Seeking Alpha is proud to welcome Richelle Cutler-Strom as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » The...

Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL )  +3.3% after-hours as Gilead’s (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic...

Genfit SA ( OTCPK:GNFTF ) initiated with Buy rating and a €46 (144% upside) price target at B. Riley FBR citing an expected positive outcome from the Phase 3 RESOLVE-IT study evaluating elafibranor in NASH. More news on: Genfit, CymaBay Therapeutics, Vertex Pharmaceuticals Incorpora...

Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce...

The Update On Genfit Pharmaceuticals Genfit ( OTCPK:GNFTF ) is a clinical stage small-cap ($653M) biopharmaceutical company that is clinically developing innovative therapeutics and biomarkers for the prevention and treatment of cardiometabolic diseases including NASH. Its lead investigati...

Quick Take Cirius Therapeutics ( CSTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm provides is developing small-molecule treatments for nonalcoholic steatohepatitis [NASH] with fibrosis. CSTX has seen promisin...

Many institutional investors will assess Cirius Therapeutics (CSTX) as the company's leading product candidate is at Phase 2 of development and results will be released in the second half of 2019. In addition, it is beneficial that the company has no debt and expects to convert all its convert...

Gilead Sciences ( GILD ) is getting ready to release NASH results in the 1st half of 2019. This will be from studies dealing with selonsertib to treat patients with NASH fibrosis. The thing is that Gilead doesn't want to hinge its entire future on selonsertib. It also wants to establish a st...

CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal...

Recently, Conatus Pharmaceuticals ( CNAT ) reported results from a phase 2b study known as ENCORE-PH. It noted that this study had failed to meet on the primary endpoint; however, there are still many shots on goal left. This is why I believe that this biotech has a chance to recover. For st...